FilingReader Intelligence

Hengrui subsidiary gets approval for heart failure drug trial

July 24, 2025 at 05:14 PM UTCBy FilingReader AI

Shandong Shengdi Pharmaceutical, a subsidiary of Jiangsu Hengrui Medicine, received approval from the National Medical Products Administration for clinical trials of HRS-1893 tablets on April 30, 2025.

The drug is a highly selective small molecule inhibitor of cardiac myosin for treating heart failure with preserved ejection fraction. Hengrui invested approximately RMB 60.67 million in research and development for HRS-1893.

The company noted no similar drugs are currently approved globally for this indication.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

SSE:600276Shanghai Stock Exchange
Shanghai Blue Chip

News Alerts

Get instant email alerts when Jiangsu Hengrui Medicine publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →